Abstract: This patent presents a formulation that safely and effectively decreases the feeling of fatigue in treated individuals. Specifically, the natural formulation decreases the feeling of general fatigue, the feeling of physical fatigue, and the feeling of mental fatigue.

Abstract: Gene-Eden-VIR is a natural product that safely and effectively decreases the level of fatigue in treated individuals.

Abstract: Gene-Eden-VIR is a natural product that decreases the severity, duration, and frequency of symptoms during a viral infection, including infections with the Human Papillomavirus (HPV), Epstein Barr Virus (EBV), Herpes Simplex Virus (HSV), Human Cytomegalovirus (HCMV), and Hepatitis C Virus (HCV).

Abstract: Geotagging is the process of adding geographical identification metadata to photographs and is a form of geospatial metadata. The current invention presents a method for determining the popularity/attractiveness of certain geographical areas by calculating the densities of the available photographs (or availability of photographs) with geodata corresponding to these geographical areas.

Abstract: The invention presents nutritional supplements with anti influenza activities. In a preferred embodiment, the invention features administration to a subject an effective dose of a nutritional supplement that includes a combination of all or some of the following ingredients licorice, quercetin, green tea, cinnamon, propolis, and selenium.

Abstract: The invention presents methods for decreasing the concentration of a foreign polynucleotide in a human or animal subject, especially, when such polynucleotide is latent in the subject.

Abstract: In one aspect, the invention presents methods for treating chronic diseases. In a preferred embodiment, the methods feature administration to a subject an effective dose of a dietary supplement that prevents or attenuates microcompetition between a foreign polynucleotide and a cellular polynucleotide or attenuates an effect of such microcompetition, especially, when the foreign polynucleotide is latent in the subject.

Abstract: A recent discovery showed that microcompetition between a foreign polynucleotide and a cellular polynucleotide is a risk factor for some of the major chronic diseases. The invention uses this novel discovery to present assays for screening compounds based on their effectiveness in modulating such microcompetition. The effective compounds can be used in treatment of these chronic diseases. The invention also presents assays for screening compounds that can be used in treatment of chronic diseases resulting from other foreign polynucleotide-type disruptions.

Abstract: Using the recently discovered biology of chronic disease, the invention presents new methods for evaluating the effectiveness of a compound for use in modulating the progression of chronic disease, for determining whether a subject has a chronic disease, or has an increased risk of developing clinical symptoms associated with such disease, and for treating chronic disease.

Abstract: Using the recently discovered biology of atherosclerosis, cancer, and alopecia, the invention presents new methods for evaluating the effectiveness of a compound for use in modulating the progression of the disease, for determining whether a subject has a disease, or has an increased risk of developing clinical symptoms associated with such disease, and for treating atherosclerosis, cancer, and alopecia.

Abstract: A recent discovery showed that microcompetition between a foreign polynucleotide and a cellular polynucleotide is a risk factor for some of the major chronic diseases. The invention uses this novel discovery to present assays for screening compounds based on their effectiveness in modulating such microcompetition. The effective compounds can be used in treatment of these chronic diseases. The invention also presents assays for screening compounds that can be used in treatment of chronic diseases resulting from other foreign polynucleotide-type disruptions.

Abstract: Microcompetition between a foreign polynucleotide and a cellular polynucleotide is a risk factor associated with chronic disease. The invention uses this novel discovery to present assays for the diagnosis of chronic disease. The assays are based on measuring the cellular copy number of the foreign polynucleotide, measuring the rate of complex formation between the microcompeted cellular transcription factor and either the foreign polynucleotide or the cellular polynucleotide, identifying modified expression of a gene susceptible to microcompetition with a foreign polynucleotide, or identifying modified activity of a gene product of a gene susceptible to microcompetition with a foreign polynucleotide.

Abstract: Microcompetition between a foreign polynucleotide and a cellular polynucleotide is a risk factor associated with chronic disease. The invention uses this novel discovery to present methods for the treatment of chronic disease. The methods are based on modifying the microcompetition between a polynucleotide natural to a subject suffering from a chronic disease and a polynucleotide foreign to the subject. Specifically, the treatment may modify the cellular copy number of the foreign polynucleotide, change the rate of complex formation between the microcompeted cellular transcription factor and either the foreign polynucleotide or the cellular polynucleotide, vary the expression of a gene susceptible to such microcompetition, or manipulate the activity of a gene product of a gene susceptible to microcompetition with a foreign polynucleotide. The invention also presents methods for the treatment of chronic disease resulting from other foreign polynucleotide-type disruptions.

Abstract: Microcompetition for GABP between a foreign polynucleotide and cellular GABP regulated genes is a risk factor associated with many chronic diseases such as obesity, cancer, atherosclerosis, stroke, osteoarthritis, diabetes, asthma, and other autoimmune diseases. The invention uses this novel discovery to present assays for the diagnosis of these chronic diseases. The assays are based on measuring the cellular copy number of the foreign polynucleotide, measuring the rate of complex formation between GABP and either the foreign polynucleotide, or a cellular GABP regulated gene, identifying modified expression of a cellular GABP regulated gene, or identifying modified activity of the gene product of a GABP regulated gene. The invention also presents other foreign polynucleotide-type assays.

Abstract: Cellular microcompetition for the transcription factor human GA binding protein (GABP) is a risk factor associated with obesity and obesity-related diseases such as osteoarthritis, atherosclerosis, obstructive sleep apnea, various cancers, and periodontitis. The invention uses this novel discovery to develop assays which determine the level of microcompetition in a cell. Other assays developed from the knowledge that microcompetition is occurring in cells are also disclosed. This novel discovery led to the development of assays which can determine the level of microcompetition in a cell and to select compounds to target this microcompetition syndrome. In addition, methods to treat a patient for microcompetition based disease are taught.

Abstract: A recent discovery showed that microcompetition for GABP between a foreign polynucleotide and a cellular GABP regulated gene is a risk factor for some of the major chronic diseases, such as obesity, cancer, atherosclerosis, stroke, osteoarthritis, diabetes, asthma, and other autoimmune diseases. The invention uses this novel discovery to present assays for screening compounds based on their effectiveness in modulating such microcompetition, or the effects of such microcompetition on the cell. The selected compounds can be used in treatment of these chronic diseases. The invention also presents assays for screening compounds that can be used in treatment of chronic diseases resulting from other foreign polynucleotide-type disruptions.

Abstract: Microcompetition for GABP between a foreign polynucleotide and a cellular GABP regulated gene is a risk factor associated with chronic disease such as obesity, cancer, atherosclerosis, stroke, osteoarthritis, diabetes, asthma, and other autoimmune diseases. The invention uses this novel discovery to present methods for the treatment of these chronic diseases. The methods are based on modifying such microcompetition, or the effect of such microcompetition on the cell. For instance, treatment may modify the cellular copy number of the foreign polynucleotide, change the rate of complex formation between GABP and either the foreign polynucleotide or the cellular GABP regulated gene, vary the expression of the cellular GABP regulated gene, or manipulate the activity of the gene product of the cellular GABP regulated gene. The invention also presents methods for treatment of chronic diseases resulting from other foreign polynucleotide-type disruptions.